Vertex Pharmaceuticals ( VRTX 2.72%) had a fine Tuesday on the stock exchange. The biotech 's shares closed the day nearly 3% ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

In new research published in Nature, Weizmann Institute scientists introduce a powerful tool to explore quantum phenomena—the ...

Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...

Vertex Pharmaceuticals got a healthy boost on Tuesday, with shares climbing nearly 3% thanks to a double dose of analyst ...